New York State Common Retirement Fund Sells 4,000 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

New York State Common Retirement Fund cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 72,228 shares of the biopharmaceutical company’s stock after selling 4,000 shares during the period. New York State Common Retirement Fund’s holdings in Alnylam Pharmaceuticals were worth $16,996,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Allworth Financial LP increased its position in shares of Alnylam Pharmaceuticals by 6.8% during the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 38 shares during the period. Huntington National Bank grew its position in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares during the period. SYM FINANCIAL Corp grew its position in Alnylam Pharmaceuticals by 6.2% in the third quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 55 shares during the period. Lindbrook Capital LLC grew its position in Alnylam Pharmaceuticals by 11.1% in the third quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 57 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its position in Alnylam Pharmaceuticals by 0.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company’s stock valued at $1,532,000 after acquiring an additional 58 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 0.2 %

Shares of Alnylam Pharmaceuticals stock opened at $250.59 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The business has a 50-day moving average of $254.14 and a two-hundred day moving average of $263.03. The company has a market capitalization of $32.44 billion, a P/E ratio of -115.48 and a beta of 0.35. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on ALNY shares. Morgan Stanley upped their price target on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Canaccord Genuity Group upped their price target on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a research report on Tuesday, February 18th. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Barclays boosted their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Finally, Piper Sandler reissued an “overweight” rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $299.48.

Insiders Place Their Bets

In related news, CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the completion of the transaction, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. This trade represents a 2.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the transaction, the executive vice president now owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 81,356 shares of company stock worth $22,498,551 over the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.